News | February 08, 2022
GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Granules India has reported consolidated financial results for the period ended December 31, 2021
This is the ninth Covid-19 vaccine approved in India
Key takeaways of recent quarter & conference call highlights
Lupin has reported consolidated financial results for the period ended December 31, 2021
It has a total of 50 ANDA approvals from USFDA
The acquisition of myPOLS Biotec complements Medix Biochemica’s leading portfolio of IVD raw materials and expands its reagent offerings for molecular diagnostics
ICICI Direct’s analysis of Cipla’s Q3FY22 results
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Subscribe To Our Newsletter & Stay Updated
